1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Delayed Nasdaq  -  04:00 2022-06-29 pm EDT
245.43 USD   +0.79%
06/15Amgen Inc. Reaffirms Revenue Guidance for the Year 2022
CI
06/15TRANSCRIPT : Amgen Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 10:40 AM
CI
06/10Amgen announces webcast of goldman sachs 43rd annual healthcare conference
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AMGEN INC : Submission of Matters to a Vote of Security Holders (form 8-K)

05/18/2022 | 04:25pm EDT

Item 5.07. Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting on May 17, 2022. The final results of the voting for each matter submitted to a vote of stockholders at the meeting are as follows:

Item 1 - Election of Directors

Each of the following 12 nominees for director were elected to serve a one-year term expiring at the Company's 2023 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier retirement, resignation, disqualification, removal or death.

Name                         Votes For      Votes Against     Abstain      Broker Non-
                                                                              Votes
Dr. Wanda M. Austin          393,262,568         6,448,766      738,582     63,585,494
Mr. Robert A. Bradway        375,943,441        21,463,442    3,043,033     63,585,494
Dr. Brian J. Druker          392,906,914         6,807,605      735,397     63,585,494
Mr. Robert A. Eckert         336,327,670        62,799,670    1,322,576     63,585,494
Mr. Greg C. Garland          364,253,481        34,483,152    1,713,283     63,585,494
Mr. Charles M. Holley, Jr.   381,334,073        17,752,766    1,363,077     63,585,494
Dr. S. Omar Ishrak           366,717,639        32,920,612      811,665     63,585,494
Dr. Tyler Jacks              392,012,356         7,712,005      725,555     63,585,494
Ms. Ellen J. Kullman         388,527,454        10,667,223    1,255,239     63,585,494
Ms. Amy E. Miles             386,328,380        12,833,592    1,287,944     63,585,494
Dr. Ronald D. Sugar          332,321,569        66,949,303    1,179,044     63,585,494
Dr. R. Sanders Williams      387,372,234        11,822,332    1,255,350     63,585,494

Item 2 - Advisory Vote to Approve Our Executive Compensation

The advisory vote to approve our executive compensation was approved.

For:                357,838,927
Against:             40,742,450
Abstain:              1,868,539
Broker Non-Votes:    63,585,494

Item 3 - Ratification of Selection of Independent Registered Public Accountants

Ernst & Young LLP was ratified as the Company's independent registered public accountants for the fiscal year ending December 31, 2022. No Broker Non-Votes resulted from the vote on this proposal.

For:       436,530,705
Against:    26,765,473
Abstain:       739,232

No other matters were submitted for stockholder action.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about AMGEN INC.
06/15Amgen Inc. Reaffirms Revenue Guidance for the Year 2022
CI
06/15TRANSCRIPT : Amgen Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference..
CI
06/10Amgen announces webcast of goldman sachs 43rd annual healthcare conference
PR
06/08BEHIND ONE BIOTECH'S WATER CONSERVAT : Saving Every Drop
PU
06/08TRANSCRIPT : Amgen Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-20..
CI
06/07Amgen - FDA APPROVES RIABNI (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN (RITUXIMAB), FOR ..
AQ
06/06NEW BPCIA COMPLAINT : Genentech Files Suit Against Tanvex Regarding Its Proposed Herceptin..
AQ
06/06Amgen Says FDA Approves Riabni to Treat Rheumatoid Arthritis
MT
06/06FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ..
PR
06/06Amgen Inc. Announces U.S. Food and Drug Administration Approves RIABNI
CI
More news
Analyst Recommendations on AMGEN INC.
More recommendations